Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
The Company remains on track to report preliminary results in the first half of 2024.
- The Company remains on track to report preliminary results in the first half of 2024.
- General and administrative expenses for both the third quarter of 2023 and 2022 were $4.5 million.
- For the third quarter of 2023, Protara reported a net loss of $9.9 million, or $0.87 per share, compared with a net loss of $7.7 million, or $0.68 per share, for the same period in 2022.
- Net loss for the third quarter of 2023 included approximately $1.4 million of stock-based compensation expenses.